Strong Volume Growth Not Enough to Justify Premium Valuation

What happened

Unilever reported Q2 2026 underlying sales growth of 5.8%, the strongest volume growth in over 15 years, driven by emerging markets and margin improvement. The company continues portfolio streamlining, including potential divestitures and the McCormick deal, which could bring capital for buybacks. Despite this, the stock remains a Hold as the valuation reflects a balanced risk-reward with little margin of safety. Macro risks and private label competition persist, and the shares trade at a rich ~32x P/E, about 39% above DCF-based intrinsic value. The market is not rewarding the growth because the premium valuation already discounts much of the improvement.

Implication

The strong volume growth is a positive sign that the Growth Action Plan is gaining traction, but it is not enough to justify the current premium valuation. Given the stock trades at ~32x trailing earnings and about 39% above DCF-based intrinsic value, the margin of safety is thin. Portfolio actions like the McCormick deal and potential divestitures may unlock value, but execution risks around the Ice Cream demerger and productivity savings remain. Macro headwinds and intensifying private label competition could pressure future growth and margins. Therefore, investors should avoid adding at current levels and consider trimming positions if overexposed, while watching for a pullback to the high-$40s/low-$50s where the risk-reward would become more attractive.

Thesis delta

Previous stance was potential sell due to rich valuation and transformation risks. The new evidence of 15-year-high volume growth (5.8% underlying sales) suggests the company's strategy is gaining traction, reducing near-term downside risk. However, the valuation remains stretched, so we moderate the stance from sell to hold, recognizing that growth momentum may support the share price but does not offer sufficient margin of safety for new investment.